Latest Period
Q1 2026
Security Snapshot
Jade Biosciences, Inc. - Common Stock (JBIO) Institutional Ownership
CUSIP: 008064206
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
118
Shares (Excl. Options)
49,846,615
Price
$14.05
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- JBIO on Nasdaq
- Shares outstanding
- 49,296,333
- Price per share
- $25.23
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 49,846,615
- Total reported value
- $700,290,229
- % of total 13F portfolios
- 0%
- Share change
- +2,597,001
- Value change
- +$35,560,462
- Number of holders
- 118
- Price from insider filings
- $25.23
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- JBIO - Jade Biosciences, Inc. - Common Stock is tracked under CUSIP 008064206.
- 118 institutions reported positions in Q1 2026.
- 12 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 102 to 118 between Q4 2025 and Q1 2026.
- Reported value moved from $726,260,386 to $700,290,229.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 118 institutions filings for Q1 2026.
Security key
008064206
Latest holder period
Q1 2026
13F holders
118
13D/G owners
12
CIK / CUSIP context first
Open Q1 2026 holders
JBIO full holder history
Jade Biosciences, Inc. SEC filings
Jade Biosciences, Inc. company facts
Jade Biosciences, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 008064206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
12
Security
JBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 0% | $89,373,614 | +$26,797,898 | 10,353,875 | +43% | Fairmount Funds Management LLC | 06 Oct 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $70,905,847 | +$26,271,533 | 5,115,862 | +59% | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2025 |
| FMR LLC | 15% | $40,965,976 | 4,735,951 | FMR LLC | 30 May 2025 | |||
| Bellevue Group AG | 6.8% | $46,307,688 | 3,341,103 | Bellevue Group AG | 16 Dec 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 7% | +72% | $27,758,364 | +$16,318,579 | 3,214,969 | +143% | RA Capital Management, L.P. | 08 Oct 2025 |
| JANUS HENDERSON GROUP PLC | 6.3% | +1.7% | $50,218,668 | +$682,568 | 3,105,669 | +1.4% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| BlackRock, Inc. | 4.7% | -27% | $32,256,341 | +$2,045,989 | 2,295,825 | +6.8% | BlackRock, Inc. | 31 Mar 2026 |
| VANGUARD GROUP INC | 4.2% | -23% | $32,337,685 | +$4,446,695 | 2,095,767 | +16% | The Vanguard Group | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 4.2% | 0% | $11,949,495 | +$379,228 | 1,384,646 | +3.3% | Frazier Life Sciences Public Fund, L.P. | 30 Sep 2025 |
| Sofinnova Venture Partners X, L.P. | 0.3% | $1,617,308 | 107,391 | Sofinnova Venture Partners X, L.P. ("SVP X") | 28 Apr 2025 | |||
| TCG Crossover GP I, LLC | 0.2% | $649,193 | 64,023 | TCG Crossover GP I, LLC | 28 Apr 2025 | |||
| Atlas Venture Fund XII, L.P. | 0.2% | $521,257 | 51,406 | Atlas Venture Associates XII, L.P. | 28 Apr 2025 |
As of 31 Mar 2026, 118 institutional investors reported holding 49,846,615 shares of Jade Biosciences, Inc. - Common Stock (JBIO). This represents 101% of the company’s total 49,296,333 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
91%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 14% | 7,085,423 | +2.8% | 0.01% | $99,550,194 |
| Fairmount Funds Management LLC | 9.2% | 4,553,494 | 0% | 4.6% | $63,976,591 |
| RA CAPITAL MANAGEMENT, L.P. | 7.4% | 3,671,083 | 0% | 0.55% | $51,578,716 |
| Bellevue Group AG | 7.1% | 3,501,502 | +4.8% | 1.2% | $49,196,103 |
| Venrock Adviser, LLC | 6.5% | 3,220,364 | 0% | 1.7% | $45,246,114 |
| JANUS HENDERSON GROUP PLC | 6.3% | 3,105,669 | 0.02% | $43,557,008 | |
| BlackRock, Inc. | 4.7% | 2,313,949 | -19% | 0% | $32,510,984 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 1,796,652 | 0% | 0% | $25,242,961 |
| BAKER BROS. ADVISORS LP | 3.3% | 1,641,137 | 0% | 0.13% | $23,057,975 |
| Remedium Capital Partners, LLC | 3.2% | 1,577,750 | 0% | 7.9% | $22,167,388 |
| Versant Venture Management, LLC | 3.1% | 1,525,820 | 0% | 15% | $21,437,771 |
| Avidity Partners Management LP | 2.8% | 1,400,708 | 0% | 3.9% | $19,679,947 |
| SAMSARA BIOCAPITAL, LLC | 2% | 968,798 | 0% | 1.3% | $13,611,612 |
| GREAT POINT PARTNERS LLC | 2% | 964,462 | +20% | 3.3% | $13,550,691 |
| MARSHALL WACE, LLP | 1.9% | 944,776 | +7.9% | 0.01% | $13,274,106 |
| Aberdeen Group plc | 1.8% | 867,284 | 0% | 0.02% | $12,185,340 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 822,520 | -2.3% | 0% | $11,559,273 |
| Soleus Capital Management, L.P. | 1.6% | 796,744 | 0% | 0.45% | $11,194,253 |
| ACORN CAPITAL ADVISORS, LLC | 1.6% | 786,760 | 3.1% | $11,053,978 | |
| STATE STREET CORP | 1.3% | 655,690 | +2% | 0% | $9,212,445 |
| Affinity Asset Advisors, LLC | 1.3% | 639,956 | -10% | 0.53% | $8,991,382 |
| Driehaus Capital Management LLC | 1.3% | 635,498 | -28% | 0.07% | $8,928,747 |
| RTW INVESTMENTS, LP | 1.2% | 573,205 | -60% | 0.08% | $8,053,530 |
| Ikarian Capital, LLC | 1% | 512,349 | +71% | 1% | $7,198,503 |
| Opaleye Management Inc. | 0.87% | 427,608 | 0% | 0.83% | $6,007,892 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q1 2026
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 49,846,615 | $700,290,229 | +$35,560,462 | $14.05 | 118 |
| 2025 Q4 | 47,075,378 | $726,260,386 | +$242,240,917 | $15.43 | 102 |
| 2025 Q3 | 31,617,300 | $272,859,518 | +$407,366 | $8.63 | 74 |
| 2025 Q2 | 31,531,484 | $315,000,764 | +$314,968,047 | $9.99 | 70 |